SCHEMBL1883379

SCHEMBL1883379

Nc1nc(-c2cccc(OCc3ccc(C(=O)O)cc3)c2)c2cc(Cl)ccc2n1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.58
RXRB P28702 2/20 0.58
RXRG P48443 2/20 0.58
NR4A2 P43354 3/20 0.53
EGLN1 Q9GZT9 2/20 0.49
BACE1 P56817 1/20 0.49
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
SLC9A3 P48764 1/20 0.47
MRGPRX4 Q96LA9 2/20 0.45
HSP90AB1 P08238 1/20 0.45
PTGER1 P34995 1/20 0.44
SRD5A2 P31213 1/20 0.44
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1880116 0.91 MRGPRX4 (0.56) NR4A2EGLN1BACE1MRGPRX4PTGER1
SCHEMBL1879985 0.91 BACE1 (0.55) RXRARXRBRXRGNR4A2EGLN1
SCHEMBL1879898 0.91 CYP3A4 (0.50) RXRARXRBRXRGNR4A2EGLN1
SCHEMBL1877697 0.87 BACE1 (0.52) NR4A2BACE1SLC9A3HSP90AB1MAOB
SCHEMBL1876600 0.87 HSP90AB1 (0.62) BACE1SMN1; SMN2SLC9A3HSP90AB1MAOB
SCHEMBL1881986 0.86 DHFR (0.55) NR4A2EGLN1BACE1SLC9A3HSP90AB1
SCHEMBL1877640 0.84 BACE1 (0.49) NR4A2BACE1SLC9A3HSP90AB1MAOB
SCHEMBL1879206 0.84 BACE1 (0.49) BACE1SLC9A3HSP90AB1MAOB
SCHEMBL1881261 0.84 MRGPRX4 (0.53) NR4A2BACE1SLC9A3MRGPRX4HSP90AB1
SCHEMBL1879428 0.83 BACE1 (0.48) EGLN1BACE1SMN1; SMN2SLC9A3HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947696-B2 heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases MERCK PATENT GMBH (DE) 2011-05-24 US claimed
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2008-09-04 US claimed
CN-101180278-A 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH (DE) 2008-05-14 CN claimed
EP-1881965-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS Merck Patent GmbH (DE) 2008-01-30 EP claimed
WO-2006122631-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS MERCK PATENT GMBH (DE) 2006-11-23 WO claimed
US-7947696-B2 heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases MERCK PATENT GMBH (DE) 2011-05-24 US disclosed
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2008-09-04 US disclosed
EP-1881965-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS Merck Patent GmbH (DE) 2008-01-30 EP disclosed
WO-2006122631-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS MERCK PATENT GMBH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators HSP90AB2P, HSP90AB1, HSP90AA1 RXRA 3086/4885RXRB 3224/4885RXRG 2927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.